Home・Aandelen Lijst・Bridgebio Pharma Inc

Bridgebio Pharma Inc

Gesloten

SectorGezondheidszorg

84.14 2.04

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

83.58

Max

84.94

Belangrijke statistieken
By Trading Economics
Inkomsten	24M -167M
Verkoop	40M 195M
EPS	-0.84
Winstmarge	-85.626
Werknemers	834
EBITDA	68M -113M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+24.96% upside

Dividenden
By Acuity
Volgende Winsten	10 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	2.3B 16B
Vorige openingsprijs	82.1
Vorige sluitingsprijs	84.14

Nieuwssentiment

By Acuity

50%

128 / 340 Rangschikking in Healthcare

Bridgebio Pharma Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

7 aug 2026, 20:03 UTC

Correlated Moves

Social Media

BridgeBio Pharma Inc is gaining traction amid strong biotech sector performance. Cantor Fitzgerald lists it as a top pick ahead of its earnings report.

6 aug 2026, 19:16 UTC

Social Media

BridgeBio Pharma Inc's shares are higher, reflecting a modest gain since Wednesday's close amid mixed market sentiment ahead of the non-farm payrolls report.

5 aug 2026, 19:16 UTC

BridgeBio Pharma Inc. shares are lower today, with no specific news identified. The stock retraced from earlier gains, reflecting broader market trends.

4 aug 2026, 19:36 UTC

Correlated Moves

Social Media

BridgeBio Pharma Inc shares rise as Piper Sandler sets a price target of $111 following the LGMD Scientific Summit. Biotech sector momentum supports the increase.

3 aug 2026, 20:06 UTC

BridgeBio Pharma Inc shares are lower today, breaking from a recent trend of higher daily closes. No specific news was identified to explain the decline.

31 jul 2026, 19:56 UTC

Correlated Moves

Social Media

BBIO shares decline, continuing a three-day trend amid sector weakness.

30 jul 2026, 20:21 UTC

Correlated Moves

BridgeBio Pharma Inc shares rose in after-market trading, reflecting positive market sentiment. The stock's performance aligns with an upward trend in the Russell 2000 Index.

29 jul 2026, 17:36 UTC

BridgeBio Pharma Inc shares are lower today, reaching a pre-market low before a slight recovery. No specific news was identified to explain the decline.

28 jul 2026, 19:07 UTC

Correlated Moves

BBIO shares lower today amid declining biotech sector sentiment.

27 jul 2026, 18:26 UTC

Social Media

BridgeBio Pharma shares are higher, supported by Bank of America’s positive pipeline commentary and a $35 million revenue estimate increase for 2026.

Peer Vergelijking

Prijswijziging

Bridgebio Pharma Inc Prognose

Koersdoel

By TipRanks

24.96% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 105.57 USD 24.96%

Hoogste 157 USD

Laagste 93 USD

Gebaseerd op 15 Wall Street-analisten die 12-maands prijsdoelen bieden voor Bridgebio Pharma Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

15 ratings

Buy

Hold

Sell

Gebaseerd op 15 analisten die aandelenratings hebben gegeven aan Bridgebio Pharma Inc - Dist in de afgelopen 3 maanden.

Sentiment

By Acuity

128 / 340 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.